Keywords: BioCryst Pharma, Green Cross, South Korea, Perarmivir, Flu vaccine
BioCryst partner Green Cross gets Korean OK to make and market peramivir flu vaccine
Article | 17 August 2010
USA-based BioCryst Pharmaceuticals says that its partner, South Korea-headquartered Green Cross Corp, has received marketing and manufacturing approval from the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
